Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 26:9:963.
doi: 10.3389/fonc.2019.00963. eCollection 2019.

Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets

Olivia G Taylor  1   2 , Joshua S Brzozowski  1   2 , Kathryn A Skelding  1   2
Affiliations
Review

Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets

Olivia G Taylor et al. Front Oncol. .

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumour in humans and has a very poor prognosis. The existing treatments have had limited success in increasing overall survival. Thus, identifying and understanding the key molecule(s) responsible for the malignant phenotype of GBM will yield new potential therapeutic targets. The treatment of brain tumours faces unique challenges, including the presence of the blood brain barrier (BBB), which limits the concentration of drugs that can reach the site of the tumour. Nevertheless, several promising treatments have been shown to cross the BBB and have shown promising pre-clinical results. This review will outline the status of several of these promising targeted therapies.

Keywords: anti-cancer drugs; brain cancer; glioblastoma; immunotherapy; targeted therapeutics.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. (2010) 60:277–300. 10.3322/caac.20073 - DOI - PubMed
    1. Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. J Med Life. (2009) 2:386–393. - PMC - PubMed
    1. Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, et al. . Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000–2008): findings of a multicenter Australian study. Surg Neurol Int. (2011) 2:176. 10.4103/2152-7806.90696 - DOI - PMC - PubMed
    1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. (2015) 17(Suppl. 4):iv1–62. 10.1093/neuonc/nov189 - DOI - PMC - PubMed
    1. Zhu P, Du XL, Lu G, Zhu JJ. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget. (2017) 8:44015–31. 10.18632/oncotarget.17054 - DOI - PMC - PubMed

LinkOut - more resources